Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-comparative, Multicentre Study to Evaluate the Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

NCT05470270 is registered in ClinicalTrials.gov with Theravia as lead sponsor.

NCT NCT05470270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05470270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-comparative, Multicentre Study to Evaluate the Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
Lead sponsor
Theravia
Phase
Phase 2
Overall status
Completed
Start date
July 8, 2022
Completion date
October 28, 2022
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease